Sangamo Therapeutics (SGMO) Tops Q4 EPS by 3c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Oil surge keeps S&P 500, Nasdaq in check before earnings; Salesforce lifts Dow
- Oil prices rise 2% as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Lumentum shares fall after hitting 52-week high
- Stryker invests $400M in CMR Surgical with option to acquire
Sangamo Therapeutics Reports Fourth Quarter And Full Year 2018 Financial Results
February 28, 2019 4:01 PM ESTBRISBANE, Calif., Feb. 28, 2019 /PRNewswire/ --Â Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today reported fourth quarter and full year 2018 financial results and recent business highlights.
Recent Highlights
ST-920 IND acceptance: The U.S. Food and Drug Administration (FDA) accepted the Investigational New... More


